Research & Reviews: Journal ofMedical and Health Sciences

e-ISSN:2319-9865
p-ISSN:2322-0104

Bipolar Disorder: ThePsychopathology

M Rekha *

Department of Pharmacy, Jawaharlal Nehru Technological University, Kakinada, India

Short Communication

Received: 07/05/2021

Accepted: 21/05/2021

Published:28/05/2021

***For Correspondence:**

M Rekha,
Department of Pharmacy,
Jawaharlal Nehru Technological University, Kakinada, India

E-mail: desai.rek@gmail.com

Keywords: Psychosocial stress; Mental disorder; Psychotherapy; Manic depression

ABSTRACT

BD is a highly recurrent and severe illness, with high rates of suicidality and functional impairment. The disorder is heritable and appears to share susceptibility genes with schizophrenia. It is characterized by dysregulation in the dopamine and serotonin systems and by pathology in the brain systems involved in regulating emotion. Psychosocial stressors, notably life events and familial expressed emotion, significantly influence the course of the illness in the context of these vulnerabilities. Findings of randomized clinical trials indicate that psychosocial interventions enhance long-term outcomes when added to pharmacotherapy.

Research & Reviews: Journal of Medical and Health Sciences

e-ISSN:2319-9865
p-ISSN:2322-0104

DESCRIPTION

Mental disorder where people switch from very happy to very sad is a greatly repeating and extreme illness, with high rates of depression and functional damage/weakness. The condition is related to things you get from your parents' genes and looks to share likelihood of being harmed or influenced tiny chemical assembly instructions inside of living things with very serious mental disorder. It is seen as dysregulation within the brain chemical and serotonin systems and by disease/the study of disease within the brain systems involved in regulation of feelings of love, hate, fear, etc. related to how people think and treat each other upsetting things, especially life events and family-related expressed feeling of love, hate, guilt, etc., significantly influence the course of the illness within the big picture of those weaknesses that could be used to hurt something or someone [1].

Findings of randomized scientific fact-finding experiments point to/show that related to how people think and treat each other actions that help bad situations improve long-term results when added to pharmacotherapy. Much remains to be cleared up about the interactive things that are given/work that's done of related to tiny chemical assembly instructions inside of living things, neurobiological, and related to how people think and treat each other factors to the course of the sickness/problem, and therefore the moderators and people who try to settle an argument of treatment effects [2].

Bipolar major affective disorder, or manic depressive illness (MDI), may be a common, severe, and protracted mental disease. This condition may be a serious lifelong struggle and challenge. Bipolar major affective disorder is characterized by periods of deep, prolonged, and profound depression that alternate with periods of an excessively elevated or irritable mood referred to as mania. Just one manic/hypomanic episode is required to diagnose bipolar instead of unipolar disorder. Manic depression is further characterized as type I or type II. Type I is diagnosed when a minimum of one manic episode is identified. Manic depression occurs in approximately 1 percent of the population. Bipolar II disorder and manic depression not otherwise specified (NOS) account for an additional 2.5 percent of the population. Manic depression is nearly always recurrent and may be related to severe illness-related morbidity and increased medical mortality. About 10 to twenty percent of patients with manic depression die of their illness by suicide. Manic depression equally prevalent in men and ladies. It's an early age onset.

The foremost common age of onset of manic depression is 17-21 years. It's a highly disabling illness, and actually a study. Manic depression is caused by biopsychosocial influences including genetic, perinatal, neuroanatomic, neurochemical and other biologic abnormalities. Additionally psychological and socioenvironmental factors are related to a greater risk of bipolar disorders. The role of genes within the susceptibility to mood disorders has long been supported by family, twin, and adoption studies. That mood disorders run in families may be a common observation of patients and clinicians. However, genes clearly only contribute a predisposition that has got to interact with environmental factors so as to cause disease. Treatment of bipolar disorders requires an integration of medical, psychological, and psychosocial inputs [3,4].

Several controlled treatment trials revealed that Mood Stabilizers and Antipsychotic approaches help a lot in stabilizing mania, while CBT, FFT, and lamotrigine seems to be more effective in depression. More research on possible pharmacological and psychological combinations is required. Perhaps using strategies to maximize the effects of different therapeutic agents on opposite poles of the disorder. Studies should also evaluate treatment staging strategies, such as stabilizing BD depressed patients on mood stabilizers and antidepressants and then determine whether adding a psychosocial intervention enables quicker discontinuation of the antidepressant [5-7].

e-ISSN:2319-9865
p-ISSN:2322-0104

CONCLUSION

BD is a highly recurrent, debilitating illness. Major strides have been made in clarifying its diagnostic boundaries, its etiology from the vantage point of basic neurobiology and psychosocial stressors, and effective treatments. Nonetheless, much remains to be clarified about the basic psychopathology and treatment of this disorder. Similar to unipolar depression, BD is characterized by pathology in the brain systems involved in regulating emotion. Given the disorder's neural correlates, it is not surprising that psychosocial variables expected to trigger negative emotions, such as negative life events and EE in caregivers, exert a major influence on the course of disorder and are particularly tied to BD depression.

REFERENCES

1. Aagaard J, et al. Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Disord. 1990;18:259–66.
2. Adler A. Problems of Neurosis. New York: Harper & Row. 1964.
3. Akiskal HS. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol. 1996;16:4–14.
4. Akiskal HS, et al. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord. 2005;85:245–58.
5. Akiskal HS, et al. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord. 2000;59:5–30.
6. Alda M. Bipolar disorder: from families to genes. Can J Psychiatry. 1997;42:378–87.
7. Alloy LB, et al. The Temple-Wisconsin cognitive vulnerability to depression project: lifetime history of Axis I psychopathology in individuals at high and low cognitive risk for depression. J Abnorm Psychol. 2000;109:403–18.